MARKET

EVAX

EVAX

Evaxion Biotech A/S
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.55
+0.74
+8.40%
After Hours: 9.00 -0.55 -5.76% 17:57 09/24 EDT
OPEN
8.83
PREV CLOSE
8.81
HIGH
9.55
LOW
8.71
VOLUME
75.64K
TURNOVER
--
52 WEEK HIGH
10.34
52 WEEK LOW
5.16
MARKET CAP
180.96M
P/E (TTM)
-12.0490
1D
5D
1M
3M
1Y
5Y
Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer
Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (...
GlobeNewswire · 4d ago
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) rose 39.7% to $26.93 in pre-market trading after jumping 278% on Wednesday. Focus Universal recently priced 2 million shares at $5 per share to raise $10 million for its initial public offering on the Nasdaq.
Benzinga · 09/02 11:06
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.
Benzinga · 09/01 16:00
EDU, SESN and GOTU among mid-day movers
Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSi...
Seekingalpha · 08/24 16:34
BRIEF-Evaxion Biotech Announces Q2 2021 Financial Results And Provides Business Update
reuters.com · 08/12 10:40
Evaxion Biotech Q2 EPS $(0.36) Down From $(0.24) YoY
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.36) per share. This is a 50 percent decrease over losses of $(0.24) per share from the same period last year.
Benzinga · 08/12 10:34
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a Phase 2b clinical trial Data also reported in early July...
GlobeNewswire · 08/12 10:30
Evaxion Biotech (NASDAQ:EVAX) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 08/03 07:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVAX. Analyze the recent business situations of Evaxion Biotech A/S through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVAX stock price target is 19.00 with a high estimate of 21.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 7
Institutional Holdings: 439.56K
% Owned: 2.29%
Shares Outstanding: 18.95M
TypeInstitutionsShares
Increased
1
5.00K
New
2
1.77K
Decreased
3
139.29K
Sold Out
5
311.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About EVAX
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Webull offers kinds of Evaxion Biotech A/S - ADR stock information, including NASDAQ:EVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVAX stock methods without spending real money on the virtual paper trading platform.